DXCM vs NVS
Dexcom vs Novartis AG — AI-powered side-by-side comparison
| Metric | DXCM | NVS |
|---|---|---|
| AI Score | 57 | 71 |
| Price | $82.66 | $154.44 |
| P/E Ratio | 31.92× | 23.58× |
| ROE | 30.5% | 30.5% |
| Revenue Growth YoY | — | — |
| Gross Margin | 62.5% | 74.3% |
| Debt / Equity | 0.53× | 1.18× |
| Dividend Yield | 0.0% | 2.9% |
| RSI (14) | 62.0 | 46.9 |
| Beta | 1.453 | 0.46 |
| Expected Upside | +6.8% | +1.2% |
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
DXCM Full Analysis
NVS Full Analysis